PRAX Stock Price, Chart, Stats & News
Praxis Precision Medicines, Inc. (PRAX) does not currently pay a dividend.
PRAX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -32.33% |
ROE | -58.74% |
D/E | 0.00x |
Interest coverage ratio | – |
PRAX valuation
P/E | – |
P/S | – |
P/B | 7.43x |
P/CF | -26.18x |
P/FCF | -24.58x |
P/OCF | -26.18x |
PEG | 4.79x |
EV multiple | -20.70x |
About
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor.
Similar securities
Based on sector and market capitalization
